Direct Lung Sampling Indicates That Established Pathogens Dominate Early Infections in Children with Cystic Fibrosis.

Peter Jorth
Zarmina Ehsan MD
Children's Mercy Hospital
Amir Rezayat
Ellen Caldwell
Christopher Pope

See next page for additional authors

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers

Part of the Pediatrics Commons, Pulmonology Commons, and the Respiratory Tract Diseases Commons

Recommended Citation

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.
Direct Lung Sampling Indicates That Established Pathogens Dominate Early Infections in Children with Cystic Fibrosis

Graphical Abstract

What organisms inhabit the lungs of children with cystic fibrosis and mild lung disease?

1. Bypass mouth and throat with endotracheal tube
2. Account for contamination

Conventional CF pathogens
- Staphylococcus
- Achromobacter
- Stenotrophomonas
- Pseudomonas
- Burkholderia
- Haemophilus

Highlights

- BALs from CF children with mild disease primarily contain established CF pathogens
- Microbiota in BALs lacking CF pathogens were indistinguishable from controls
- Rare oral organisms were found in some BALs containing abundant CF pathogens
- CF pathogens strongly correlated with inflammation and oral organisms did not

Authors
Peter Jorth, Zarmina Ehsan, Amir Rezayat, ..., Dan Benscoter, John P. Clancy, Pradeep K. Singh

Correspondence
john.clancy@cchmc.org (J.P.C.), singhpr@uw.edu (P.K.S.)

In Brief
Jorth et al. studied lung lavages from CF children using sequence-based methods and extensive controls for upper airway and reagent contamination. The results argue against the CF infection pathogenesis hypothesis postulating that diverse communities of mostly oral bacteria inhabit lungs early in disease and suggest that differences in the samples' microbial diversity were driven by changes in the abundance of conventional CF pathogens against a fairly constant background of contaminants.
Direct Lung Sampling Indicates That Established Pathogens Dominate Early Infections in Children with Cystic Fibrosis

Peter Jorth,1,2 Zarmina Ehsan,3,8 Amir Rezayat,2,8 Ellen Caldwell,4 Christopher Pope,8 John J. Brewington,6,7 Christopher H. Goss,4 Dan Benscoter,6,7 John P. Clancy,6,7,9,* and Pradeep K. Singh2,9,10,*

1Departments of Pathology and Laboratory Medicine, Medicine, and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
2Department of Microbiology and Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
3Pulmonology and Sleep Medicine, Children’s Mercy-Kansas City, Kansas City, MO 64108, USA
4Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
5Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195, USA
6Division of Pulmonary Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
7Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
8These authors contributed equally
9These authors contributed equally
10Lead Contact
*Correspondence: john.clancy@cchmc.org (J.P.C.), singhpr@uw.edu (P.K.S.)
https://doi.org/10.1016/j.celrep.2019.03.086

SUMMARY

Culture and sequencing have produced divergent hypotheses about cystic fibrosis (CF) lung infections. Culturing suggests that CF lungs are uninfected before colonization by a limited group of CF pathogens. Sequencing suggests diverse communities of mostly oral bacteria inhabit lungs early on and diversity decreases as disease progresses. We studied the lung microbiota of CF children using bronchoscopy and sequencing, with measures to reduce contamination. We found no evidence for oral bacterial communities in lung lavages that lacked CF pathogens. Lavage microbial diversity varied widely, but decreases in diversity appeared to be driven by increased CF pathogen abundance, which reduced the signal from contaminants. We found no evidence for oral bacterial communities in lung lavages that lacked CF pathogens. Lavage microbial diversity varied widely, but decreases in diversity appeared to be driven by increased CF pathogen abundance, which reduced the signal from contaminants. Streptococcus, Prevotella, and Veillonella DNA was detected in some lavages containing CF pathogens, but DNA from these organisms was vastly exceeded by CF pathogen DNA and was not associated with inflammation. These findings support the hypothesis that established CF pathogens are primarily responsible for CF lung infections.

INTRODUCTION

People with cystic fibrosis (CF) suffer from chronic bacterial lung infections that culminate in respiratory failure (Burns et al., 2001; Emerson et al., 2002; Lyczak et al., 2002). Despite intensive research, key questions about CF infection pathogenesis remain obscure. One fundamental question is which bacterial species are present in the lungs of people with CF and which cause disease. Addressing this question is critical to devising effective disease prevention and treatment approaches.

Decades of study using culture-based methods suggest that the lungs of people with CF are uninfected at birth and that over time transient and then permanent infections develop (Burns et al., 2001). Importantly, a restricted group of organisms (called “CF pathogens” below) have been thought responsible for infection. The list of CF pathogens include Haemophilus influenzae, Staphylococcus aureus, Pseudomonas aeruginosa, Burkholderia spp., and a few others (Gibson et al., 2003; Lyczak et al., 2002); epidemiological and clinical observations associate these organisms with disease (Emerson et al., 2002; Gibson et al., 2003).

Recent work using DNA sequencing to identify bacteria in CF airways has produced several new ideas that have challenged this established model. First, DNA-based methods suggest that diverse communities of bacteria that were not previously thought to cause CF infections (a group we call “non-conventional organisms” below) dominate lungs before CF pathogens appear, when lung function is generally preserved (Brown et al., 2014; Coburn et al., 2015; Frayman et al., 2017; Madan et al., 2012; Mühlebach et al., 2018; Pittman et al., 2017). This finding raises the possibility that non-conventional organisms could protect lungs from pathogen infection. Alternatively, these organisms could produce initial lung injury that promotes pathogen colonization.

Second, although studies using DNA-based methods generally find that CF pathogens dominate lung microbiota in advanced disease (Coburn et al., 2015; Goddard et al., 2012; Zhao et al., 2012), sequence-based analyses indicate that diverse communities of non-conventional organisms co-exist with CF pathogens after CF pathogens become dominant (Coburn et al., 2015; Zhao et al., 2012). This finding raises the possibility that non-conventional organisms could either enhance or dampen pathogen-induced injury or treatment responses, or independently contribute to disease.
Finally, DNA-based analyses suggest that the diversity of lung microbiota may be a key disease parameter. Many studies have found that the relative abundance of non-conventional organisms and the diversity of lung microbiota in airway samples decrease as age and disease severity advances (Coburn et al., 2015; Cox et al., 2010; Fodor et al., 2012; Klepac-Ceraj et al., 2010; Stokell et al., 2015; Zhao et al., 2012). This finding raises the possibility that declining diversity could contribute to lung disease and strategies that maintain diversity could be beneficial.

Reconciling the new ideas suggested by DNA-based methods with the established pathogenesis model is challenging, as both culture- and DNA-based approaches have significant and in some ways opposing limitations. Culture analysis is based on the premise that infection is generally caused by a single or small number of pathogens that can be isolated in pure culture (Baron et al., 2013; Burns and Rolain, 2014). Thus, clinical laboratories selectively culture samples and filter results to remove organisms not considered pathogenic (Tunney et al., 2008), which are viewed as contaminants (Baron et al., 2013; Mahboubi et al., 2016). This could be problematic, as culture-based analysis could fail to identify non-conventional organisms.

In contrast, DNA-based methods cast a wider net, identifying culturable and unculturable organisms and DNA from live and dead cells without filtering for contaminants (Kennedy et al., 2014; Sailer et al., 2014; Weiss et al., 2014). This could be problematic because many of the non-conventional organisms detected by sequencing are highly abundant in oropharyngeal secretions that contaminate airway samples (Blk et al., 2010; Coburn et al., 2015; Cox et al., 2010; Dewhirst et al., 2010; Fodor et al., 2012; Goddard et al., 2012; Klepac-Ceraj et al., 2010; Lim et al., 2013; Price et al., 2013; Twomey et al., 2013; Zemanick et al., 2015; Zhao et al., 2012). Contamination is particularly problematic for throat and sputum samples and when lung bacterial biomass is low (e.g., early in disease), as contaminants will have more consequential effects on measurements (Coburn et al., 2015; Sailer et al., 2014). DNA-based methods could also detect bacteria that are inhaled or aspirated but killed by host defenses before they replicate. Thus, DNA-based methods will detect contaminants and dead organisms that do not actively grow in the lung.

Here, we sought to investigate the composition of lung microbiota in CF children by combining the high sensitivity of sequence-based approaches and directed bronchoscopic sampling, with measures to reduce exposure to oropharyngeal secretions and extensive controls to help identify contaminants. We focused on CF children, as the results of culture- and DNA-based methods differ most in early lung disease and understanding early infection is critical to intervention strategies to preserve lung function.

RESULTS

Subjects

We studied 22 children and young adults (mean, 13.1 years old; range, 6–21 years old) all with mild CF lung disease (mean forced expiratory volume [FEV₁], 92% ± 15% predicted) who underwent bronchoscopy for clinical indications. None of the subjects were taking cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Table S1 provides additional information about study subjects.

Sampling Approach and Controls

Reducing and controlling for contamination are particularly critical when using DNA-based methods due to their sensitivity and because results are not filtered by clinical laboratories that disregard and remove organisms considered to be contaminants. Bronchoalveolar lavage (BAL) samples may become contaminated with bacterial DNA from the oropharyngeal compartment, secretions aspirated into the lung during the procedure, and non-patient sources, including the bronchoscope and reagents (Culver et al., 2003; Kennedy et al., 2014; Kirschke et al., 2003; Mehta and Minai, 1999; Sailer et al., 2014; Srinivasan et al., 2003; Weiss et al., 2014).

We eliminated scope contact with oropharyngeal mucosa and likely reduced procedure-associated aspiration by performing bronchoscopy through cuffed endotracheal tubes placed during a separate laryngoscopy procedure (Figure 1A); however, some upper airway secretions likely entered the endotracheal tube during placement. We also collected mouth rinses and throat aspirates by using a sterile suction catheter immediately before bronchoscopy from each subject for comparison (Figure 1B).

Using these methods, we performed BAL of 4 lobar bronchi in each subject (with the scope in the wedged position, see STAR Methods), beginning with the right middle lobe from which 2 saline lavages were separately collected (BAL-1a and b). Lavage was subsequently performed in an adjacent segmental bronchus in the right upper lobe (BAL-2), then the left lower lobe (BAL-3), and finally in the lung segment that appeared most diseased during bronchoscopy or on prior imaging (BAL-4) (Figure 1A).

DNA contamination contributed by reagents and the suction channels of bronchoscopes and catheters (which were used for throat aspirates) are difficult to reduce. Thus, we measured bacterial DNA in saline washes (saline from same source that was used for BALs) from each bronchoscope and catheter, immediately before bronchoscopies and throat aspirates were performed (called “scope or catheter pre-washes” or collectively called “instrument controls,” below) as background measurements of contamination from non-patient sources (Figure 1B).

Measuring Background Contamination in BALs

Scope pre-washes consistently contained ~10² bacterial genome copies/mL (Figures S1A and S1B; Table S2) (mean, 293; range, 43–651), similar to instrument and reagent controls in other studies (Table S3). Sequencing revealed a diverse collection of microbial DNA in scope pre-washes, including CF pathogens (see Figure 1C for genera considered CF pathogens) (Figure S1C; Tables S4 for taxa and S5 for sequencing read counts and Good’s coverage for each sample). The fact that DNA-based analysis of instrument control samples identified CF pathogens (see below) prior to contact with subjects highlights one challenge in interpreting sequencing results.

Two findings indicated that most bacterial DNA in scope washes originated from processing reagents, rather than the
scope channel. Bacterial DNA abundances in scope and catheter pre-washes and in saline used for controls (and subsequent BALs) that was not passed through any device were similar (Figure S1A). In addition, the microbiota profiles of scope and catheter pre-washes exhibited different patterns depending on the reagent batches used for processing sequencing libraries (Figure S1C).

We tested the hypothesis that scope pre-washes would represent the contaminating DNA in subsequently obtained BALs by serially passing 10-mL saline aliquots through 3 bronchoscopes used in this study and found bacterial DNA abundance essentially unchanged in serial samples (Figure S1B). This finding indicates that the background DNA signal (likely derived from reagents, see Figure S1C) would also likely be detectable in BALs. We accounted for this contamination in the analyses of BALs described below.

**BALs from CF Children Vary Widely in Bacterial DNA Abundance**

We measured the total bacterial burden in all mouth, throat, BAL, and control samples. BAL bacterial DNA concentrations ranged from $10^2$ to $10^6$ genome copies/mL (levels seen in scope pre-wash controls) to $10^6$ genome copies/mL, which was higher than any other sample type (Figure 1D; Table S2). Notably, the bacterial concentration in serial BAL samples taken from the same subject sometimes differed by an order of magnitude (Figure S2; Table S3).
The Non-conventional Organisms in BALs Are Similar to Instrument Pre-wash Controls

We focused further analysis on the non-conventional organisms in BALs because the identity and origins of these organisms are a key area of controversy in CF (O’Toole, 2018). Previous work suggests that many non-conventional organisms in CF airway samples are oral organisms (Bik et al., 2010; Coburn et al., 2015; Cox et al., 2010; Dewhirst et al., 2010; Fodor et al., 2012; Goddard et al., 2012; Klepac-Ceraj et al., 2010; Lim et al., 2013; Price et al., 2013; Twomey et al., 2013; Zemanick et al., 2015; Zhao et al., 2012). Some studies suggest that these organisms inhabit CF lungs, whereas other studies raise the possibility that they are contaminants introduced from oropharyngeal secretions. However, relatively few studies have used bronchoscopy sampling performed through endotracheal tubes placed during a separate laryngoscopy procedure as done here, and we hoped that this approach would limit oropharyngeal contamination (see above).

We began by ordering the BALs by their total bacterial DNA abundance (Figure 3A) and found that non-conventional organisms generally dominated BALs with low bacterial abundance, whereas CF pathogens dominated BALs with high abundance (Figure 3B). We then examined the similarity of each BAL to subject-paired mouth and throat samples using the Morisita-Horn dissimilarity index (Wolda, 1981).

As expected, the high biomass BALs that were dominated by CF pathogens (Figure 3B, right side of graph) were very dissimilar to their paired mouth and throat samples (Figures 3C, 3D, and 4). This finding is consistent with data indicating that CF pathogens are not abundant in the mouth and throat (Figure S5; Table S4). Surprisingly, the low bacterial biomass BALs that were dominated by non-conventional organisms (Figures 3B, left side of graph) were also very dissimilar to subject-paired mouth and throat samples (Figures 3C, 3D, and S5; Table S4).

The dissimilarity of low bacterial biomass BALs to mouth and throat samples led us to hypothesize that contaminants contributed by reagents and instruments may account for the non-conventional organism DNA in these samples. We tested this hypothesis in three ways. First, we compared BALs to their paired scope pre-wash controls and found the BALs with low bacterial DNA abundance to be more similar to subject-paired scope pre-washes than to paired mouth and throat samples (compare Figures 3E to 3C and 3D).

Second, we plotted the relative abundance of taxa in BALs as a function of their abundance in instrument controls. Taxa that were instrument or reagent contaminants would likely show a linear abundance relationship in these two sample types, whereas taxa originating from subjects’ lungs should be more abundant in BALs relative to instrument controls. As shown in Figure 3F, the relative abundance of non-conventional taxa (black points) in instrument controls and BALs exhibited a strong linear relationship. In contrast, CF pathogens (colored points) were more abundant in BALs than in instrument controls.

Third, we computationally removed CF pathogens from the results to increase the resolution of the non-conventional organisms present and compared BALs to mouth, throat, and control samples. Regardless of total bacterial DNA content, the taxonomic profiles of non-conventional organisms in...
Figure 2. Changes in the Absolute Abundance of CF Pathogens Drive BAL Shannon Diversity Differences

(A) Relationship between the Shannon diversity index and bacterial DNA recovered from the first BAL obtained from each subject (BAL-1a). Bacterial DNA recovery was measured by subtracting bacterial DNA levels in patient-paired scope pre-washes from the values in subsequent BAL-1a sample; n = 17 as samples from 5 subjects (i.e., 5, 6, 8, 17, and 18) were not included because BAL samples contained lower bacterial concentrations than paired scope pre-washes. (B and C) Relationship between BAL Shannon diversity and total bacterial DNA levels in all 102 BALs (B) and 22 mouth rinses (C) collected (see Figure S3 for data from throat samples). Linear regression lines with 95% confidence intervals and Pearson correlation coefficients with p values are shown in (A)–(C). (D and E) Relationship between the absolute abundance of CF pathogens (D) and non-conventional organisms (E) and Shannon diversity indices of BALs (n=102). Linear regression lines and Pearson correlation coefficients with respective p values are shown. (F) Absolute abundance of CF pathogens and non-conventional organisms in the 25 BALs with the lowest (left) and highest (right) Shannon diversity indices (mean values for each group are indicated in black bars). Error bars indicate SD values; *p < 0.005, unpaired two-tailed t test. (G and H) Data from the 102 BALs presented in (D) and (E), but plotted in terms of relative rather than absolute abundance of CF pathogens (G) and non-conventional organisms (H). The relative abundance plots obscure the finding that CF pathogen abundance drives the Shannon diversity differences. Graphs include linear regression and Pearson correlation coefficients with respective p values. Here and below taxa abundance data obtained from sequencing are the mean of 3 technical replicates. Also see Figures S3 and S4, Table S4 for taxa abundance data, and Table S5.
BALs were more similar to catheter and scope pre-wash controls than to mouth or throat samples (Figure 4A). Morisita-Horn dissimilarity and principal coordinates analyses corroborated these findings (Figures 4B and 4C). Furthermore, principal coordinates analyses showed that non-conventional organisms in BALs grouped with instrument control samples that were processed using the same reagent batches (Figure 4C). These findings are consistent with the strong reagent-batch effect on the microbiota identified in saline and instrument controls (Figure S1). Taken together, these findings suggest that most of non-conventional organisms in the BALs we studied were dissimilar to patient-paired oral samples and were likely contaminants contributed by processing reagents.

**BALs Lacking CF Pathogens Did Not Contain Microbiota Distinguishable from Background**

Although the similarity and clustering analyses above suggest that reagent contaminants contribute significantly to the non-conventional organisms in the BALs we collected, the findings do not rule out the possibility that some non-conventional organisms originate from the lungs. We used two approaches to examine this possibility further, focusing first on BALs that contained very low abundances of CF pathogens (less than 150% of the maximum pathogen DNA levels found in paired scope pre-washes, i.e., <164 CF pathogen genome copies/mL).

First, we plotted the relative abundance of non-conventional taxa found in these BALs as a function of their abundance in instrument controls. As noted above, taxa that originated from the subjects’ lungs would be expected to be more abundant in BALs. As shown in Figure 3G, the abundance of non-conventional taxa in BALs and instrument controls exhibited a strong linear relationship, with values falling along the identity line.

We also used a statistical test (the negative binomial test [Love et al., 2014]) to identify non-conventional organisms over-represented in BALs, relative to paired instrument and reagent controls and found no taxa that were overrepresented in low pathogen abundance BALs as compared to scope pre-wash samples (Table 1) (see Table S6 for proof-of-principle control analyses). Thus, these analyses found no evidence for an identifiable microbiota that was distinct from instrument controls in BALs containing a low abundance of CF pathogens.

Some Pathogen-Infected BALs Contained DNA from Oral Bacteria

We used the statistical analysis described above to determine if any non-conventional organisms were overrepresented in BALs that did contain CF pathogens (i.e., BALs with >164 CF pathogen genome copies per mL, which is >150% of the maximum value in instrument and reagent controls). In contrast to the results from low pathogen abundance BALs, we found three non-conventional genera, *Streptococcus*, *Prevotella*, and *Veillonella*, over-represented in BAL samples relative to controls (Table 1). In addition, an uncultured organism belonging to the Alcaligenaceae family was overrepresented. Alcaligenaceae includes *Achromobacter*, *Burkholderia*, and *Bordetella*, so reads assigned to Alcaligenaceae may have come from one of these CF pathogens. These findings suggest that *Streptococcus*, *Prevotella*, and *Veillonella* genera may be present at a low abundance in BALs that already contained CF pathogens.

**Streptococcus, Prevotella, and Veillonella Are Vastly Outnumbered by Pathogens**

Examination of the profiles of non-conventional organisms (with pathogens removed) (Figure 4A) suggested that *Streptococcus*, *Prevotella*, and *Veillonella* were more abundant in BALs that contained more bacterial DNA. To examine this further, we plotted the absolute abundance of *Streptococcus*, *Prevotella*, and *Veillonella* as a function of the total BAL bacterial DNA concentration (Figure 5A) and CF pathogen abundance (Figure 5B) and found a strong positive relationship. With the exception of 6 (out of 102) BALs that contained trace levels of *Streptococcus* DNA (~10 genome copies/mL), *Streptococcus*, *Prevotella*, and *Veillonella* were absent in BALs containing <1,000 bacterial genome copies/mL (Figure 5A) or <100 CF pathogen genome copies/mL (Figure 5B).

We examined the ratio of *Streptococcus*, *Prevotella*, and *Veillonella* to CF pathogens in BALs and found CF pathogens in far excess abundance. On average, there was 725-fold more pathogen DNA than *Streptococcus*, 2,334-fold more pathogen DNA than *Prevotella*, and 6,476-fold more pathogen DNA than *Veillonella* (Figure 5C). Thus, these three non-conventional organisms were almost always found in BALs that already contained abundant pathogens (Figure 5B) and, when present, were far outnumbered by CF pathogens (Figure 5C). These findings are consistent with supplemental data presented by Hogan et al. (2016) (see their
Figure 4. Non-conventional Organisms in BALs Are Similar to Scope and Catheter Pre-washes but Different from Paired Mouth and Throat Samples

(A) Relative abundance of non-conventional taxa detected in all 102 BALs (top); and 22 catheter and scope pre-washes, mouth and throat samples (bottom) after CF pathogens were computationally removed.

(B) Morisita-Horn dissimilarity of non-conventional organisms in all 102 BALs (after pathogens were removed) as compared to non-conventional organisms in subject-paired scope pre-wash, mouth rinse, and throat aspirate samples. Mean and SEM are indicated.

(C) Principal coordinates analysis of Morisita-Horn dissimilarities of non-conventional organisms (after pathogens removed) in BAL, mouth rinse, throat aspirate, and instrument control samples described in (A). The scope and catheter pre-wash control samples separate into two groups along principle coordinate 1 according to the batch in which they were sequenced.
Multivariate Analyses Implicate CF Pathogens in Lung Inflammation

Although CF pathogens are generally acknowledged to cause CF lung inflammation, the effect of oral organisms that may inhabit lungs is less clear. Indeed, both beneficial (Filkins et al., 2012; Zemanick et al., 2013) and detrimental (Conrad et al., 2013) effects on inflammation have been postulated.

We first used pairwise linear regression models and found that the BAL abundance of CF pathogens, Streptococcus, Veillonella, and Prevotella each correlated with neutrophil elastase, a robust marker of disease-causing inflammation (Sagel et al., 2007) (Figure 5D). However, Streptococcus, Veillonella, and Prevotella and CF pathogen abundances were strongly correlated in these BALs (Figure 5B), so pairwise associations could be spurious.

We, thus, used multivariate regression modeling, and again found CF pathogen abundance significantly associated with neutrophil elastase levels in all models tested (Figure 5E). Indeed, for each log_{10} increase in CF pathogen abundance, neutrophil elastase increased by nearly 0.4 log_{10} µg/mL. For reference, the primary anti-inflammatory medicine used in CF (azithromycin) was found to reduce neutrophil elastase by 0.2 log_{10} g/mL (Saiman et al., 2003). In contrast, models incorporating Prevotella, Streptococcus, or Veillonella abundance identified no positive or negative effect of these organisms (Figure 5E). Prevotella, Streptococcus, and Veillonella exhibited significant collinearity and could not be analyzed in the same model.

Effect of Treatment on Results

We investigated the potential effects of antibiotic and anti-inflammatory medications on the data. We found no differences in BAL bacterial DNA abundance or neutrophil elastase in subjects that were (n = 16) or were not (n = 6) taking antibiotics and were (n = 15) or were not (n = 7) taking anti-inflammatorieds (Figures S7B–S7E). Principle coordinate analysis of Morisita-Horn dissimilarities showed that the BALs did not cluster based on antibiotic use (Figure S7F). Indeed, the batch of reagents used for processing appeared to have a more pronounced effect than antibiotics (Figure S7G). Furthermore, the abundance of Streptococcus, Veillonella, and Prevotella was actually higher in BALs from antibiotic-treated subjects (Figure S7H). These observations may be related to our finding that Streptococcus, Veillonella, and Prevotella were more abundant in BALs with more CF pathogens and argue against antibiotic use as an explanation for the low abundance of oral organisms detected in these BALs.

Sequencing Can Produce False Positive Results

The strong association between CF pathogens and inflammation indicates that the accurate detection of pathogens is critical. We compared CF pathogen identification by clinical laboratory cultures and sequencing, limiting analysis to BALs studied by both methods. As shown in Figure 6A, in 11/14 cases, the CF pathogen genera identified by the clinical laboratory were also identified as highly abundant by 16S sequencing. In 2/18 BALs (from subjects 7 and 8), the clinical lab identified multiple CF pathogens, and in these cases, only 1 pathogen was detected by sequencing. However, culture detection of CF pathogens was generally corroborated by sequencing results.

In contrast, our data indicate that it could be challenging to use sequencing data in isolation to determine if CF pathogens are present or absent. On average, 13% of the sequences in scope and catheter pre-washes mapped to CF pathogens (Figure S1C) even though these control samples were obtained prior to any contact with subjects. Furthermore, BALs from the 3 subjects that were culture negative for pathogens (subjects 6, 9, and 15) and whose BAL-1a had low levels of neutrophil elastase contained CF pathogen sequences at a relative abundance of 5%, 14%, and 16% (Figure 6B).
A. Abundance of indicated taxa or group per genome copies/ml:

- Streptococcus
- Prevotella
- Veillonella
- CF Pathogens

B. Abundance of indicated taxa per genome copies/ml:

- Streptococcus
- Prevotella
- Veillonella

C. Ratio of CF pathogens to indicated taxa:

- Streptococcus
- Prevotella
- Veillonella

D. Correlation coefficients (r) and p-values:

- r = 0.81, p < 0.0001
- r = 0.56, p = 0.0009
- r = 0.67, p = 0.0007
- r = 0.61, p = 0.0028

E. Change in log_{10}(neutrophil elastase μg/ml) associated with change in indicated parameter:

- Model 1
  - Age (years)
  - Pathogens log_{10}(genome copies/ml)
  - Log_{10}(NE μg/ml)

- Model 2
  - Age (years)
  - Pathogens log_{10}(genome copies/ml)
  - Streptococcus log_{10}(genome copies/ml)

- Model 3
  - Age (years)
  - Pathogens log_{10}(genome copies/ml)
  - Prevotella log_{10}(genome copies/ml)

- Model 4
  - Age (years)
  - Pathogens log_{10}(genome copies/ml)
  - Veillonella log_{10}(genome copies/ml)

Legend:

- Azithromycin effect
- No effect

(legend on next page)
These findings are consistent with supplemental data from Hogan et al., (2016) (Table S2 in Hogan et al., 2016) indicating that washes from bronchoscopes inserted to the level of the vocal cords, but not entering subjects’ lungs, contained an average of 24% CF pathogens. Notably, the CF pathogen genera present in the scope wash controls and culture-negative BALs from our study and scope washes from Hogan et al., (2016) included *Pseudomonas*, *Burkholderia*, *Achromobacter*, and others that typically prompt clinical treatment. These data suggest that accurate sequence-based detection of CF pathogens could be problematic without extensive measures to minimize and account for background contamination.

Figure 5. CF Pathogens Vastly Outnumber Non-conventional CF Organisms in BALs and Are Associated with Lung Inflammation

(A) The absolute abundance of CF pathogens, *Streptococcus*, *Prevotella*, and *Veillonella* in all 102 BALs plotted as a function of total BAL bacterial abundance. (B) The absolute abundance of *Streptococcus*, *Prevotella*, and *Veillonella* in all 102 BALs plotted as a function of CF pathogen abundance. (C) Ratios of the abundance of CF pathogens to *Streptococcus*, *Prevotella*, and *Veillonella* in all 102 BALs. Mean and SD are indicated. (D) Pairwise correlation analyses of neutrophil elastase levels with CF pathogens, *Prevotella*, *Streptococcus*, and *Veillonella* in 22 BALs. Pearson correlation coefficients and p values are shown, and red designates significant correlation (**p < 0.05, ***p < 0.0005). Red dashed line indicates no effect on neutrophil elastase, and the red arrow shows the negative effect of azithromycin on neutrophil elastase levels identified in Saiman et al., (2003) for reference.

See also Figures S6 and S7.

Figure 6. Sequence-Based Bacterial Identification Generally Agrees with Culture but Can Produce False Positives

(A) Sequencing and culture results of 18 BALs (i.e., BAL-4 samples) that were studied by both approaches. Taxa relative abundance (from sequencing) are shown at left, and dashed boxes indicate taxa detected by culture. Culture results are listed at right, and pathogens indicated in red were not detected by sequencing at appreciable levels (<1% relative abundance). We investigated the *Bordetella* results (indicated by a cross [✝]) by subjecting the *Bordetella* reference sequence in the Silva database to BLAST analysis in the NCBI 16S rRNA database, and found the *Bordetella* reference highly similar to *Achromobacter* sp. Thus, reads mapping to *Bordetella* may have originated from *Achromobacter*, as indicated by culture results. *M. abscessus* (indicated by *) may not have been detected by sequencing because procedures used may not have lysed mycobacterial cells. (B) CF pathogens were detected in culture-negative BALs. Stacked bar graphs show relative abundance of CF pathogens (colored bars) and non-conventional organisms (black bars) in 3 culture-negative BALs and their subject-paired instrument control samples. The percentage of bacterial DNA mapping to CF pathogens is listed below each bar.

These findings are consistent with supplemental data from Hogan et al., (2016) (Table S2 in Hogan et al., 2016) indicating that washes from bronchoscopes inserted to the level of the vocal cords, but not entering subjects’ lungs, contained an average of 24% CF pathogens. Notably, the CF pathogen genera present in the scope wash controls and culture-negative BALs from our study and scope washes from Hogan et al., (2016) included *Pseudomonas*, *Burkholderia*, *Achromobacter*, and others that typically prompt clinical treatment. These data suggest that accurate sequence-based detection of CF pathogens could be problematic without extensive measures to minimize and account for background contamination.
DISCUSSION

We studied BALs from children with CF to address the following questions about CF infection pathogenesis.

Do Diverse Communities of Mostly Oral Organisms Dominate CF Lungs before Pathogens?
The analyses comparing BALs to subject-paired mouth and throat samples indicated that the bacterial DNA in BALs with low (essentially background) levels of CF pathogens were generally very different from subjects’ mouth and throat samples (see Figures 3, 4, and S5) but similar to subject-paired instrument controls. A statistical test corroborated these findings, finding no non-conventional taxa that were statistically more abundant in low-pathogen BALs than in instrument controls. Thus, these findings do not support the idea that diverse communities of oral organisms colonize lungs before CF pathogens.

Do Diverse Communities of Non-conventional Organisms Co-exist with Pathogens?
Neither the negative binomial test nor the analysis that computationally removed CF pathogen reads found evidence for high-diversity communities of non-conventional organisms in BALs in which pathogens were abundant (Figure 4). However, this analysis did identify three non-conventional taxa (Streptococcus, Prevotella, and Veillonella) that were over-represented in these BALs relative to controls. Notably, these organisms were not over-represented (relative to instrument controls) in BALs that lacked pathogens (Table 1, Figures 3G, 4A, and 5B), and when present, they were vastly outnumbered by pathogens (Figure 5C). Furthermore, multiple regression analysis found that whereas CF pathogen abundance exhibited a strong positive association with airway inflammation, neither positive nor negative effects of the low-abundance pathogens likely drive inflammation, our data raise questions about the established model’s postulate that only CF pathogens are present. The low abundance of Streptococcus, Prevotella, and Veillonella DNA found in BALs that contained CF pathogens raises the possibility that these organisms can cause superinfection of pathogen-infected lungs. If this were the case, they could contribute to disease independently or by interactions with established pathogens. However, previous work also suggests that patients with more cough and more advanced disease may experience more aspiration (Blondeau et al., 2008; Blondeau et al., 2010); thus, it is possible that the low abundance of Streptococcus, Prevotella, and Veillonella DNA in BALs could be a consequence of increased aspiration of oral secretions. These findings, together with the regression modeling data finding no association between Streptococcus, Prevotella, and Veillonella abundance with pathogen-associated inflammation indicate that additional work is needed to determine if and how these organisms might affect disease.

How Do We Interpret Differences in Microbial Diversity Indices?
Studies using DNA-based analyses suggest that microbial diversity measurements (which are calculated from relative abundance data) are a key disease parameter as strong inverse relationships between diversity and lung function and age have been observed (Coburn et al., 2015; Cox et al., 2010; Fodor et al., 2012; Klepac-Ceraj et al., 2010; Stokell et al., 2015; Zhao et al., 2012). Indeed, our study produced analogous findings, as we found strong inverse relationships between Shannon diversity and BAL bacterial abundance (Figure 2B) and neutrophil elastase (Figure S7A).

However, interpreting BAL diversity differences in the context of absolute bacterial abundance data and accounting for contaminants present in subject-paired scope pre-washes suggested that decreases in BAL diversity were due to an increased absolute abundance of CF pathogens added to a relatively constant background of non-conventional organisms that were highly similar to the organisms present in scope pre-wash controls (see Figures 2D–2F). In other words, decreases in BAL diversity appeared to be due primarily to increases in CF pathogens reducing the signal from contaminants. Importantly, an analogous mechanism could operate in sputum samples as increases in CF pathogen abundance could reduce the signal from diverse bacterial communities in contaminating oropharyngeal secretions.

Implications for CF Infection Pathogenesis
Although our findings were consistent with two major predictions of the established pathogenesis model (i.e., identifiable microbiota were not detected before pathogen infection and pathogens likely drive inflammation), our data raise questions about the established model’s postulate that only CF pathogens are present. The low abundance of Streptococcus, Prevotella, and Veillonella DNA found in BALs that contained CF pathogens raises the possibility that these organisms can cause superinfection of pathogen-infected lungs. If this were the case, they could contribute to disease independently or by interactions with established pathogens. However, previous work also suggests that patients with more cough and more advanced disease may experience more aspiration (Blondeau et al., 2008; Blondeau et al., 2010); thus, it is possible that the low abundance of Streptococcus, Prevotella, and Veillonella DNA in BALs could be a consequence of increased aspiration of oral secretions. These findings, together with the regression modeling data finding no association between Streptococcus, Prevotella, and Veillonella abundance with pathogen-associated inflammation indicate that additional work is needed to determine if and how these organisms might affect disease.

Comparing Results with Other Studies
Comparing results from studies that use DNA-based analyses is challenging because of differences in patient characteristics, specimen collection and processing and sequencing approaches, and methods used to control for contaminants. Although several factors may explain differences between our results and previous work analyzing CF airway microbiomes (Carmody et al., 2013; Coburn et al., 2015; Cox et al., 2010; Filkins et al., 2012; Frayman et al., 2017; Hogan et al., 2016; Pittman et al., 2017; Renwick et al., 2014; Whiteson et al., 2014; Zemanick et al., 2013; Zemanick et al., 2015; Zhao et al., 2012), we speculate that one key factor was the use of cuffed endotracheal tubes for bronchoscopy that were inserted by laryngoscopy under general anesthesia. This approach eliminated scope contact with the oropharynx and likely reduced contamination with oropharyngeal secretions. The saliva of CF children has been reported to contain an average of $10^{10}$ bacteria/mL (Zemanick et al., 2015). Thus, mixing as little as 1/100 of a milliliter of saliva into 10 mL of BAL fluid or sputum could produce a signal reporting ~$10^6$ oral bacteria per mL. The sampling approach used here likely reduced upper airway contamination and, thus, decreased detection of oral organisms. Other studies have used different approaches to control for contaminants, including using multiple bronchoscopes and protected brushes to sample the airways (Hogan et al., 2016), sequencing reagent control samples (Muhlebach et al., 2018), and sequencing oropharyngeal control samples (Zemanick et al., 2015), and the different methods could produce different results.

Previous work using BAL is somewhat more analogous to this study, but comparisons are still hampered by methodological
differences. For example, studies that reached different conclusions about the abundance of oral organisms in CF lungs either studied infants or very young children (Frayman et al., 2017; Muhlebach et al., 2018; Pittman et al., 2017), did not analyze data in reference to paired instrument or oropharyngeal controls (Frayman et al., 2016), and in some cases performed BAL through laryngeal masks (Frayman et al., 2017; Pittman et al., 2017; Rennie et al., 2014) or trans-orally (Frayman et al., 2016) rather than by endotracheal tubes. Finally, as indicated above, interpreting differences in diversity indices between samples using absolute and relative taxa abundance values can lead to different conclusions. We speculate that these factors account for some of the different conclusions reached between this and other studies.

Study Limitations
Our study had several limitations. First, we collected cross-sectional samples and more complete information about early infections requires longitudinal sampling. For example, it is possible that oral organisms could be present periodically and transiently affect disease manifestations. Second, subjects underwent bronchoscopy for varying clinical indications and were on physician-directed (rather than protocol-directed) treatments, and this likely introduced variability to the findings. The use of bronchoscopies for clinical indications and the lack of longitudinal samples are difficult to avoid given the risks of general anesthesia, endotracheal intubation, and bronchoscopy in children.

Third, the DNA-based methods we used do not distinguish organisms that are living and replicating in the lung from those that are deposited in the airways and then rapidly killed. This is particularly important for interpreting the low abundance of Streptococcus, Prevotella, and Veillonella in BALs dominated by pathogens, as work in non-CF subjects suggests that oral bacteria may be aspirated and rapidly cleared from lungs (Dickson et al., 2017). It is also important to note that although the statistical analysis found no evidence for these or other oral organisms in BALs without pathogens, it is possible that they are present at very low abundances and could not be resolved from background contaminants. In addition, this analysis compared the values and variance of taxa present in all BAL and controls as groups, and some BALs could be outliers in terms of taxa composition.

Fourth, it was impractical to directly measure the absolute abundance of each taxon identified. Thus, we calculated absolute abundances from measurements of total bacterial genome copies and taxa relative abundance. Our validation experiments suggest this approach is reasonable. Finally, we sampled a limited number of lung sites (usually 4), only used BAL, did not study non-CF children, CF children less than 5 years old, or those with advanced disease, and did not have a cohort undergoing defined pulmonary exacerbations. Sampling more sites, protected specimen brushes, and studying different subjects could produce different results.

Conclusions
Identifying the bacteria infecting the lungs of CF children is extremely challenging because the lungs lie distal to the heavily colonized oropharynx, lung bacterial biomass can be low, and reagents contain significant contaminating DNA. Additional work is needed that uses stringent sampling, extensive controls, absolute abundance measurements, and perhaps novel approaches (such as differential immunoglobulin coating to identify bacterial origin). This work will be critical because future progress depends upon accurately determining which bacteria are present in the lungs of people with CF and contribute to disease.

STAR METHODS
Detailed methods are provided in the online version of this paper and include the following:
- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Human subjects
- **METHOD DETAILS**
  - Study design and sample collection
  - DNA isolation
  - Bacterial quantification
  - 16S rRNA gene sequencing
  - 16S rRNA gene sequencing analyses
  - Quantification of OTU absolute abundances
  - Neutrophil elastase activity assays
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **DATA AND SOFTWARE AVAILABILITY**

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.celrep.2019.03.086.

ACKNOWLEDGMENTS
We thank the participants who made this study possible. P.J. was supported by fellowships from the Cystic Fibrosis Foundation (JORTH14F0 and JORTH17F5). This study was supported by the Cystic Fibrosis Foundation, University of Washington and University of Cincinnati’s CF Research Development programs, NIH (K24HL102246, P30DK098507, and P30DK1117467), and the Burroughs Wellcome Fund (BFWF1006700). We thank C. Penland for advice and encouragement, and L. Hoffman and C. Manrol for helpful discussions and critical review of the manuscript.

AUTHOR CONTRIBUTIONS

DECLARATION OF INTERESTS
The authors declare no competing interests.

Received: June 13, 2018
Revised: December 17, 2018
Accepted: March 22, 2019
Published: April 23, 2019
REFERENCES

Baron, E.J., Miller, J.M., Weinstein, M.P., Richter, S.S., Gilligan, P.H., Thoms-
(2013). A guide to utilization of the microbiology laboratory for diagnosis of
infectious diseases: 2013 recommendations by the Infectious Diseases Society
of America (IDSA) and the American Society for Microbiology (ASM)(a). Clin.
Infect. Dis. 57, e22–e121.

Bik, E.M., Long, C.D., Armitage, G.C., Loomer, P., Emerson, J., Mongodin,
Bacterial diversity in the oral cavity of 10 healthy individuals. ISME J.
5, 482–494.

Blondeau, K., Dupont, L.J., Mertens, V., Verleden, G., Malrifoot, A., Vandens-
aspiration of gastric contents in adult patients with cystic fibrosis. Gut 57,
1049–1055.

Blondeau, K., Pauwels, A., Dupont, L.J., Mertens, V., Proesmans, M., Orel, R.,
istics of gastroesophageal reflux and potential risk of gastric content aspiration

Brown, P.S., Pope, C.E., Marsh, R.L., Qin, X., McNamara, S., Gibson, R.,
Burns, J.L., Deutsch, G., and Hoffman, L.R. (2014). Directly sampling the

Burns, J.L., and Rolain, J.M. (2014). Culture-based diagnostic microbiology in

Burns, J.L., Gibson, R.L., McNamara, S., Yim, D., Emerson, J., Rosenfeld, M.,
tudinal assessment of Pseudomonas aeruginosa in young children with cystic

Caporaso, J.G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F.D.,
(2010). QIIME allows analysis of high-throughput community sequencing

Carmody, L.A., Zhao, J., Schloss, P.D., Petrosino, J.F., Murray, S., Qin, X.,
Culture-independent analysis of cystic fibrosis airway microbiota at pulmonary

Coburn, B., Wang, P.W., Caballero, J., Clark, S.T., Brahma, V., Donald-
Soc. 12, 10241–10247.

Conrad, D., Haynes, M., Salamon, P., Rainey, P.B., Youle, M., and Rohwer, F.

Cox, M.J., Allgaier, M., Taylor, B., Baek, M.S., Huang, Y.J., Daly, R.A., Karaoz,
and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One
5, e11044.


Dickson, R.P., Erb-Downward, J.R., Freeman, C.M., McCloskey, L., Falkow-
the Healthy Human Lower Respiratory Tract. Mbio 8, e02287-16.

Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., and Gibson, R.L.
(2002). Pseudomonas aeruginosa and other predictors of mortality and

Fodor, A.A., Klein, E.R., Gilpin, D.F., Elborn, J.S., Boucher, R.C., Tunney,
is stable over time and infection type, and highly resilient to antibiotic treatment

Frayman, K.B., Armstrong, D.S., Carzino, R., Ferkol, T.W., Grimwood, K.,
airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis.
Thorax 72, 1104–1112.

Care Med. 168, 918–951.

Goddard, A.F., Staudingher, B.J., Dowd, S.E., Joshi-Datar, A., Wolcott, R.D.,
fibrosis lungs indicates that RNA-based analyses of upper-airway specimens
can misrepresent lung microbiota. Proc. Natl. Acad. Sci. USA 109, 13769–
13774.

Fibrosis Transmembrane Conductance Regulator Function Reduces Airway
Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung

Hogan, D.A., Williger, S.D., Doblen, E.L., Hampton, T.H., Stanton, B.A., Moni-
son, H.G., Sogin, M.L., Czum, J., and Ashare, A. (2016). Analysis of Lung Mi-
crobiota in Bronchoalveolar Lavage, Protected Brush and Sputum Samples
from Subjects with Mild-To-Moderate Cystic Fibrosis Lung Disease. PLoS
One 17, e0149998.


Jorth, P., Turner, K.H., Gurus, P., Nizam, N., Buduneli, N., and Whiteley, M.
(2014). Metatranscriptomics of the human oral microbiome during health
and disease. MBio 5, e01012–e01014.

Kennedy, K., Hall, M.W., Lynch, M.D., Moreno-Hagelsieb, G., and Neufeld,

contamination associated with a manufacturing defect in bronchoscopes.

Klepac-Ceraj, V., Lemon, K.P., Martin, T.R., Allgaier, M., Kembel, S.W., Knapp,
ship between cystic fibrosis respiratory tract bacterial communities and age,
genotype, antibiotics and Pseudomonas aeruginosa. Environ. Microbiol. 12,
1293–1303.

Lim, Y.W., Schmieder, R., Haynes, M., Williner, D., Furlan, M., Youle, M.,
Metagenomics and metatranscriptomics: windows on CF-associated viral


Madin, J.C., Koestler, D.C., Stanton, B.A., Davidson, L., Moulton, L.A., Hous-
Serial analysis of the gut and respiratory microbiome in cystic fibrosis in in-
fancy: interaction between intestinal and respiratory tracts and impact of nutri-
tional exposures. Mbio 3, e00251-12.


## STAR METHODS

### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bacterial Strains</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pseudomonas aeruginosa PAO1</td>
<td>Manoil Lab, University of Washington</td>
<td>PAO1</td>
</tr>
<tr>
<td><strong>Biological Samples</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human cystic fibrosis bronchoalveolar lavage samples, oral washes, and post-pharyngeal aspirates</td>
<td>Cincinnati Children’s Hospital</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RNA-Bee</td>
<td>Tel-test</td>
<td>Cat# CS501B</td>
</tr>
<tr>
<td>RNAlater</td>
<td>Invitrogen</td>
<td>Cat# AM7021</td>
</tr>
<tr>
<td>Lysing matrix B</td>
<td>MP Biomedical</td>
<td>Cat# 116911500</td>
</tr>
<tr>
<td>Chloroform</td>
<td>Fisher</td>
<td>Cat# C607SK-1</td>
</tr>
<tr>
<td>Isopropanol</td>
<td>Fisher</td>
<td>Cat# A416-500</td>
</tr>
<tr>
<td>Linear acrylamide</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# AM9520</td>
</tr>
<tr>
<td>TE Buffer pH 8.0</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# AM9849</td>
</tr>
<tr>
<td>Ethanol</td>
<td>Fisher</td>
<td>Cat# A4094</td>
</tr>
<tr>
<td>3 M sodium acetate pH 5.5</td>
<td>Invitrogen</td>
<td>Cat# AM9740</td>
</tr>
<tr>
<td>SYBR FAST qPCR Master Mix</td>
<td>Kapa Biosystems</td>
<td>Cat# KK4602</td>
</tr>
<tr>
<td>HiFi HotStart ReadyMix</td>
<td>Kapa Biosystems</td>
<td>Cat# KK2602</td>
</tr>
<tr>
<td>600 cycle v3 MiSeq Reagent Kit</td>
<td>Illumina</td>
<td>Cat# MS-102-3003</td>
</tr>
<tr>
<td>MeO-suc-Ala-Ala-Pro-Ala-p-nitroanilide</td>
<td>Sigma Aldrich</td>
<td>Cat# M4765</td>
</tr>
<tr>
<td><strong>Critical Commercial Assays</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Library Quantification Kit for Illumina</td>
<td>Kapa Biosystems</td>
<td>Cat# KK4828</td>
</tr>
<tr>
<td>High Sensitivity D1000 ScreenTape</td>
<td>Agilent</td>
<td>Cat# 5067-5584</td>
</tr>
<tr>
<td>SequlPrep Normalization Plates</td>
<td>Applied Biosystems</td>
<td>Cat# A1051001</td>
</tr>
<tr>
<td><strong>Deposited Data</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacterial 16S rRNA sequencing data</td>
<td>NCBI SRA</td>
<td>Genbank: PRJNA495633</td>
</tr>
<tr>
<td><strong>Oligonucleotides</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primers for bacterial 16S rRNA sequencing, see Table S7</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>Primer 16S-CCF-qPCR-F: CCAGACTCCTACGGGCAGC</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>Primer 16S-926R-qPCR-F: CCGTCAATTYYTTTRAGTTT</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Software and Algorithms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Qiime</td>
<td>Caporaso et al., 2010</td>
<td><a href="http://qiime.org">http://qiime.org</a></td>
</tr>
<tr>
<td>Prism GraphPad</td>
<td>Prism</td>
<td><a href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</a></td>
</tr>
</tbody>
</table>

### CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Pradeep K. Singh (singhpr@uw.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS

Human subjects
Patients were enrolled at the Cincinnati Children’s Hospital Medical Center with IRB approval. Twenty-two subjects between the ages of 2-21 years old (14 females and 8 males) were recruited for participation in this prospective study if they had a documented diagnosis of CF and were undergoing clinically indicated bronchoscopies. Participation in the study was voluntary, and participants and/or parents provided informed consent prior to enrollment. We did not examine associations between subjects’ gender and results as the study objectives were to investigate using stringent sampling methods, multiple types of control samples, taxa absolute abundance data, and within-subject comparisons to interpret BAL microbiome and inflammatory marker data.

METHOD DETAILS

Study design and sample collection
Samples were collected in the following order to limit and control for possible contamination sources. (1) An oral saline rinse was collected to sample the mouth. (2) Sterile saline was drawn through a sterile catheter and saved as the first instrument control sample (called “catheter pre-wash”). (3) Using the catheter, a post-pharyngeal aspirate was collected. (4) Before beginning bronchoscopy, the second instrument control sample was collected by drawing sterile saline through the bronchoscope (called “scope pre-wash”). (5) Patients were intubated to reduce oropharyngeal contamination during the bronchoscopy.

BAL for clinical care is generally performed in only 1-2 lobes as per the ATS guidelines (Faro et al., 2015), and use either fixed volumes of 10 to 50 mL per aliquot or weight-based volumes, typically 1 ml/kg per aliquot. The right middle lobe and lingula are the lung segments most frequently sampled because they provide maximal return. Here we sampled four sites to increase the lung regions sampled. The bronchoscope was inserted into the airways without suctioning if possible, and 2 BAL samples were collected consecutively from two adjacent segmental bronchi of the right middle lobe (BAL-1a and BAL-1b). The second lavage (BAL-2) was then performed in a segmental bronchus of the right upper lobe. The bronchoscope was then repositioned to the left lower lobe (BAL-3) and in the lung segment that appeared most diseased during bronchoscopy, or on prior imaging (BAL-4).

All samples were immediately preserved in RNAlater solution to enable isolation of DNA and RNA from each sample. For a subset of samples, a portion of the untreated sample was immediately frozen for later comparison to the RNAlater treated samples. Taxonomic analyses showed that preservation in RNAlater did not affect the microbes detected in the samples by sequencing. Following collection, the BAL-4 was sent to the Cincinnati Children’s Hospital Medical Center Clinical Laboratory for microbial culturing.

DNA isolation
BAL, mouth rinse, throat aspirate, and bronchoscope and catheter pre-wash samples were thawed on ice, and DNA was isolated using RNA-Bee, as previously described (Jorth et al., 2014). For each sample, 100 μL sample was combined with 1 ml RNA-Bee In a lysing matrix B bead beating tube (MP Biomedical) and bead beat 3 times for 60 s each, incubating on ice for 1 m in between each bead beating. Lysed supernatants were mixed with 200 μl chloroform (Fisher) and shaken vigorously for 45 s. Samples were centrifuged at 13,100 g for 30 m at 4 °C to separate organic and aqueous phases. Organic phases from each sample were mixed with 500 μL TE buffer pH 8.0 (Thermo Fisher Scientific), shaken vigorously for 30 s, and incubated for 10 m on a tube roller at 25 °C. Samples were centrifuged at 13,100 g for 30 m at 4 °C to separate organic and aqueous phases. The DNA-containing aqueous phase was combined with 750 μL 100% ethanol, 25 μL 3 M sodium acetate pH 5.5, and 1 μL 5 mg/ml linear acrylamide (Thermo Fisher Scientific) to precipitate DNA. Samples were mixed by gentle inversion and incubated for at least 1 h at -80 °C. Samples were centrifuged at 16,100 g for 15 m at 4 °C to pellet DNA. DNA pellets were resuspended in 750 μL 75% ethanol and centrifuged at 16,100 g for 5 m at 4 °C to wash the DNA. A second 75% ethanol was performed, and ethanol was removed. DNA pellets were air-dried for 5 m at 25 °C and DNA was dissolved in 22 μL TE buffer pH 8.0.

Bacterial quantification
Bacteria were quantified in triplicate with 16S qPCR using 16S-CCF-qPCR-F and 16S-926R-qPCR-R primers (Table S7) with SYBR FAST qPCR Master Mix (Kapa Biosystems) using the manufacturer’s protocol with a CFX96 Touch Real-Time PCR Detection System (Biorad). Genomic DNA from P. aeruginosa PAO1 was used to generate a standard curve for quantification of genome copies per ml of sample. A negative control sample (no template) was included with every standard curve. For every experiment, a standard curve was run alongside samples.

16S rRNA gene sequencing
Sequencing libraries were produced by PCR amplification of 16S rRNA gene V3-V5 variable regions in triplicate reactions using 5 μL DNA per reaction with HiFi HotStart ReadyMix (Kapa Biosystems) using the manufacturer’s protocol on a CFX96 Touch Real-Time PCR Detection System (Biorad). PCR was performed in triplicate for each library. Indexed primers 926BC01-926BC96 (Table S7) were used to uniquely identify each library, and primers contained Illumina-compatible DNA sequences for MiSeq sequencing. For each library the triplicate PCR reactions were pooled. Pooled library reactions were purified and normalized using SequlPrep Normalization Plates (Applied Biosystems), according to the manufacturer’s instructions. Normalized indexed sequencing libraries
were combined and quantified using qPCR with the Library Quantification Kit for Illumina sequencing platforms (Kapa Biosystems). Library size was verified and by Tape Station analysis with a High Sensitivity D1000 ScreenTape (Agilent) and taken into account for quantification. The 16S rRNA gene sequencing libraries were sequenced on an Illumina MiSeq using paired 300 bp sequencing with a 600 cycle v3 MiSeq Reagent Kit (Illumina) using custom primers MiSeq-926R, MiSeq-926R-Index, and MiSeq-CCF, which were spiked into MiSeq reagent cartridge wells 12, 13, and 14, respectively (Table S7).

16S rRNA gene sequencing analyses
Qiime was used to assign sequencing reads to OTUs, calculate Shannon alpha diversity for each sample, and calculate beta diversity using the Morisita-Horn method (Caporaso et al., 2010; Horn, 1966). For each sequencing library, the 300 bp read 1 sequencing reads were processed for Qiime using custom scripts. Reads were assigned OTUs by Uclust searching against the Silva rRNA database (Quast et al., 2013). For each sample, reads were rarefied ten times to equal depth, 10,000 reads per sample. Alpha diversity was quantified by calculating Shannon diversity for rarefied samples. Morisita-Horn jackknifed beta diversity was calculated with a depth of 10,000 reads per sample when all taxa were included. Pathogen-free taxonomic profiles were generated by filtering out Staphylococcus, Pseudomonas, Haemophilus, Burkholderia, Stenotrophomonas, Achromobacter, Burkholderia, Bordetella, Inquilinus, and Escherichia-Shigella from the OTU table. Morisita-Horn jackknifed beta diversity was calculated with a depth of 465 genome copies/ml (since these BAL samples have more bacterial content than the instrument controls and would likely have true non-conventional organisms present) to the control group, which consisted of all catheter pre-wash, bronchoscope pre-wash, and reagent control samples. As a proof-of-principle we also compared the oropharyngeal samples consisting of all oral and throat samples to the same control samples. DESeq2 was used to compare non-conventional CF taxa in BAL versus control samples, as well as oropharyngeal versus control samples (Love et al., 2014).

Quantification of OTU absolute abundances
OTUs were quantified in this study by multiplying the total bacterial abundance determined by 16S rRNA gene qPCR by the relative abundances of each OTU determined by bacterial 16S rRNA gene sequencing. As proof of principle, the same analysis was performed using our previous 16S rRNA gene qPCR and sequencing data from CF sputum collected in Ireland (Hisert et al., 2017). To assess the validity of this quantification method, Pearson correlation analysis was used to compare the extrapolated OTU quantities for Streptococcus, Prevotella, Pseudomonas, Staphylococcus, and Haemophilus to the quantities of these organisms determined by genera-specific qPCR analysis.

Neutrophil elastase activity assays
Neutrophil elastase activity assays were performed on the BAL1a samples from all 22 patients by spectrophotometric detection of the hydrolysis of MeO-suc-Ala-Ala-Pro-Ala-p-nitroanilide (Sigma Chemical Co, St. Louis, MO). As controls, untreated BAL-1a samples were compared to RNAlater treated BAL-1a samples from subjects 18, 19, and 20, and negligible differences were observed.

QUANTIFICATION AND STATISTICAL ANALYSIS
Pearson and Spearman correlation analyses were performed using Prism GraphPad. Multivariate linear regression was used to examine independent effects on BAL neutrophil elastase of CF pathogens, Streptococcus, Prevotella, and Veillonella adjusted for subject age. Neutrophil elastase was non-normally distributed and required log transformation. We employed model diagnostics as follows: assessment of Studentized residuals; assessment of leverage by plotting leverage versus residuals-square, Cook’s Distance (Cook’s D), DFFIT (a measure of overall measure of influence) and DFBETA. Models were rerun without influential points and outliers to assess changes in coefficients. Quantile-quantile (q-q) plots (qqplots) of residuals were made to assess distribution of residuals. No influential data points were identified that altered the coefficients. Additional plots were of residuals against predicted values were done to assess for evidence of heteroscedasticity along with the White test. Coefficients are presented as the point estimate with 95% confidence intervals and p values. A p value of ≤ 0.05 was considered significant by convention. Graphs and statistical analyses were prepared with Prism GraphPad, Qiime, Microsoft Excel, and SAS® software (Caporaso et al., 2010; SAS, 2014).

DATA AND SOFTWARE AVAILABILITY
Sequencing read data are available in the NCBI Sequence Read Archive under Bioproject accession number PRJNA495633.